Cardiorenal benefits of sodium-glucose co-transporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in type 2 diabetes without cardiovascular and renal diseases

被引：0
作者：
Qiu, Mei [1 ]
Zhou, Xian [2 ]
Zhang, Miao [3 ]
机构：
[1] Shenzhen Longhua Dist Cent Hosp, Dept Gen Med, Guanlan Ave 187, Shenzhen 518110, Peoples R China
[2] Kunming Med Univ, Yanan Hosp, Dept Gen Med, Kunming, Yunnan, Peoples R China
[3] Beijing Univ Chinese Med, Shenzhen Hosp, Dept Nephrol, Shenzhen, Peoples R China
来源：
DIABETES OBESITY & METABOLISM | 2022年 / 24卷 / 03期
关键词：
cardiovascular; CVRD-free; death; DPP4i; renal; SGLT2i; type; 2; diabetes;
D O I：
10.1111/dom.14588
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：575 / 577
页数：3
相关论文
共 10 条
[1]  
Amod A, 2020, DIABETES THER, V11, P53, DOI [10.1007/s13300-019-00715-x, 10.2337/dci19-0066]
[2]   Lower cardiorenal risk withsodium-glucosecotransporter-2 inhibitors versus dipeptidyl peptidase-4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study [J].
Birkeland, Kare I. ;
Bodegard, Johan ;
Banerjee, Amitava ;
Kim, Dae Jung ;
Norhammar, Anna ;
Eriksson, Jan W. ;
Thuresson, Marcus ;
Okami, Suguru ;
Ha, Kyoung Hwa ;
Kossack, Nils ;
Mamza, Jil Billy ;
Zhang, Ruiqi ;
Yajima, Toshitaka ;
Komuro, Issei ;
Kadowaki, Takashi .
DIABETES OBESITY & METABOLISM, 2021, 23 (01) :75-85
[3]  
Deng M., 2021, EUR J PREV CARDIOL, V9, P1356
[4]   Sodium-glucose co-transporter-2 inhibitors for the prevention of cardiorenal outcomes in type 2 diabetes: An updated meta-analysis [J].
Giugliano, Dario ;
Longo, Miriam ;
Caruso, Paola ;
Maiorino, Maria Ida ;
Bellastella, Giuseppe ;
Esposito, Katherine .
DIABETES OBESITY & METABOLISM, 2021, 23 (07) :1672-1676
[5]   Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care [J].
Idris, Iskandar ;
Zhang, Ruiqi ;
Mamza, Jil Billy ;
Ford, Mike ;
Morris, Tamsin ;
Banerjee, Amitava ;
Khunti, Kamlesh .
DIABETES OBESITY & METABOLISM, 2021, 23 (10) :2207-2214
[6]   Lower heart failure and chronic kidney disease risks associated with sodium-glucose cotransporter-2 inhibitor use in Japanese type 2 diabetes patients without established cardiovascular and renal diseases [J].
Komuro, Issei ;
Kadowaki, Takashi ;
Bodegard, Johan ;
Thuresson, Marcus ;
Okami, Suguru ;
Yajima, Toshitaka .
DIABETES OBESITY & METABOLISM, 2021, 23 :19-27
[7]   Outcomes of patients with type 2 diabetes treated with SGLT-2 inhibitors versus DPP-4 inhibitors. An Italian real-world study in the context of other observational studies [J].
Longato, Enrico ;
Bonora, Benedetta Maria ;
Di Camillo, Barbara ;
Sparacino, Giovanni ;
Tramontan, Lara ;
Avogaro, Angelo ;
Fadini, Gian Paolo .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2021, 179
[8]   SGLT-2 inhibitors reduce the risk of cerebrovascular/cardiovascular outcomes and mortality: A systematic review and meta-analysis of retrospective cohort studies [J].
Mascolo, Annamaria ;
Scavone, Cristina ;
Scisciola, Lucia ;
Chiodini, Paolo ;
Capuano, Annalisa ;
Paolisso, Giuseppe .
PHARMACOLOGICAL RESEARCH, 2021, 172
[9]   Sodium-glucose co-transporter-2 inhibitors with and without metformin: A meta-analysis of cardiovascular, kidney and mortality outcomes [J].
Neuen, Brendon L. ;
Arnott, Clare ;
Perkovic, Vlado ;
Figtree, Gemma ;
de Zeeuw, Dick ;
Fulcher, Greg ;
Jun, Min ;
Jardine, Meg J. ;
Zoungas, Sophia ;
Pollock, Carol ;
Mahaffey, Kenneth W. ;
Neal, Bruce ;
Heerspink, Hiddo J. L. .
DIABETES OBESITY & METABOLISM, 2021, 23 (02) :382-390
[10]   Sodium-glucose co-transporter-2 inhibitors and all-cause mortality: A meta-analysis of randomized controlled trials [J].
Silverii, Giovanni Antonio ;
Monami, Matteo ;
Mannucci, Edoardo .
DIABETES OBESITY & METABOLISM, 2021, 23 (04) :1052-1056
1